Frozen Platelets in the Treatmentof Traumatic or Vascular Bleeding
Status:
Not yet recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
Primarily due to its logistical advantages The Netherlands Armed Forces (NLAF) have been
successfully using deep frozen (-80°C) platelets (DTC) for the treatment of (massive)
bleeding trauma patients in austere environments since 2001. However, high-quality evidence
for effectiveness and safety in the treatment of these type of patients is currently lacking.
The MAssive transfusion of Frozen bloOD (MAFOD) trial is therefore designed to compare the
haemostatic effect of DTCs versus room temperature stored platelets (RSP) in the treatment of
trauma- and vascular bleeding.